Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis -- Ignore unavailable to you. Want to Upgrade?

To: Steve Becker who wrote (168)	2/4/1998 9:18:00 PM
From: tommysdad	Read Replies (1) \| Respond to of 296

Press release about Terrell and Novartis: yahoo.com

To: Steve Becker who wrote (168)	2/5/1998 12:39:00 PM
From: Tom Wilkes	Read Replies (1) \| Respond to of 296

Dear Brad, Paul, Steve and others . . . Since Novartis can claim to have won the Super Bowl for the Broncos (applause, applause . . . another Broncos fan, here), that means that the ultimate credit goes to all of us who have invested in the company (more applause). Yes, the Terrell Davis deal will help Novartis' exposure in this country. I am concerned about the Smithkline/Glaxo deal, however. What do you think it means for Novartis?

To: Steve Becker who wrote (168)	2/11/1998 2:50:00 PM
From: Starlight	Read Replies (1) \| Respond to of 296

Steve - I'm new here on the Novartis topic, but I thought all of you might be interested in something I learned yesterday about this company. I toured a research lab at the UCSD Medical School where they are doing research on rheumatoid arthritis. Novartis is a corporate partner in this research. The researchers have isolated a peptide in collagen that they think causes RA. They removed one cell in the peptide and treated it with monoclonal antibodies, then put it back in the peptide and replicated it to make a solution that in nasal spray form is given to the patient. They are now in Phase I trials with patients to prove the safety of the drug and determine dosage. So far, ALL patients given the maximum dosage (25 mg.) have shown favorable results -- i.e., less inflamation and pain -- and even some of the weakest dosage patients (can't remember the exact dose-- maybe 2.5 mg.) have expressed some relief of symptoms. The drug seems to turn off the inflamatory response. Additionally, THERE HAVE BEEN NO ADVERSE SIDE EFFECTS REPORTED. Keep in mind that it will be some time yet before this is proven successful, as they still have to do Phase II and Phase III trials, which will involve many more patients and will be done in medical centers in different cities. This is still several years away, but the progress made so far (which has taken 10 yrs.) is very exciting. Also exciting is the fact that this treatment "model" could possibly be used for other diseases or illnesses. This could open up many possibilities. I think Novartis will be exciting to watch. Betty